-

Agomab to Present at 40th Annual J.P. Morgan Healthcare Conference and Announces Additional Upcoming Conference Participations in Q1

GHENT, Belgium--(BUSINESS WIRE)--Agomab Therapeutics NV (‘Agomab’) today announced that Tim Knotnerus, Chief Executive Officer, will present a company overview and update at the virtual 40th Annual J.P. Morgan Healthcare Conference on Thursday, January 13 at 8:00 a.m. ET (14:00 CET).

In addition, Agomab will participate in the following financial conferences over the next quarter:

  • SVB Leerink Global Healthcare Conference – held virtually on February 14-15, 2022
  • Cowen 42nd Annual Healthcare Conference – Boston, USA on March 7-9, 2022
  • Oppenheimer 32nd Annual Healthcare Conference – March 15-16, 2022

About Agomab

Agomab is translating a deep expertise in growth factor biology to pioneer and develop novel treatments that aim to resolve fibrosis, repair tissue structure and restore organ function. Combining new scientific insights with robust drug development and a long-term corporate vision, we are building a broad clinical pipeline of differentiated programs with disease modifying potential in severe organ failure and fibrotic diseases.

Contacts

For Agomab Therapeutics
Tim Knotnerus, CEO
E-Mail: tim.knotnerus@agomab.com

Media Requests for Agomab
Dr. Stephanie May or Dr. Laura Mittmann
Trophic Communications
Phone: +49 171 185 56 82 or + 49 151 5798 4222
E-Mail: agomab@trophic.eu

Industry:

Agomab Therapeutics NV

Release Versions
English

Contacts

For Agomab Therapeutics
Tim Knotnerus, CEO
E-Mail: tim.knotnerus@agomab.com

Media Requests for Agomab
Dr. Stephanie May or Dr. Laura Mittmann
Trophic Communications
Phone: +49 171 185 56 82 or + 49 151 5798 4222
E-Mail: agomab@trophic.eu

Social Media Profiles
Agomab on LinkedIn
More News From Agomab Therapeutics NV

Late-Breaking Interim STENOVA Data for AGMB-129 in Fibrostenosing Crohn’s to be Presented at Digestive Disease Week® 2025

ANTWERP, Belgium--(BUSINESS WIRE)--Agomab Therapeutics NV (‘Agomab’) today announced that interim data from the ongoing STENOVA1 Phase 2a clinical trial for AGMB-129, an oral gastro-intestinal (GI)-restricted small molecule inhibitor of ALK5 (TGF-β RI or ALK5) for the potential treatment of Fibrostenosing Crohn’s Disease (FSCD), will be presented as a late-breaking presentation at Digestive Disease Week® (DDW) 2025, taking place in San Diego on May 3-6, 2025. STENOVA is a randomized, double-bli...

Agomab Announces Positive Topline Phase 2a Interim Results for AGMB-129 in Fibrostenosing Crohn’s Disease

ANTWERP, Belgium--(BUSINESS WIRE)--Agomab Therapeutics NV (‘Agomab’) today announced positive interim results from 44 patients completing treatment in the ongoing STENOVA1 Phase 2a clinical trial for AGMB-129, an oral gastro-intestinal (GI)-restricted small molecule inhibitor of ALK5 (TGF-β RI or ALK5) for the potential treatment of Fibrostenosing Crohn’s Disease (FSCD). STENOVA is a randomized, double-blind, placebo-controlled study in a total of 90 patients with symptomatic FSCD. Patients are...

Agomab Announces the Appointment of Former Sandoz CFO Colin Bond to its Board of Directors

ANTWERP, Belgium--(BUSINESS WIRE)--Agomab Therapeutics NV (‘Agomab’) today announced the appointment of Colin Bond to the company’s Board of Directors as a non-executive Director and Chairman of the Audit Committee. With an extensive career in finance that spans over three decades at leading international corporations, Colin also brings fifteen years of experience as a CFO at listed biopharmaceutical companies in Switzerland, Germany and the US. “We welcome Colin to our Board of Directors,” sai...
Back to Newsroom